Description
Adjuvant in the therapy of cervico-vaginitis, vulvo-vaginitis caused by Trichomonas vaginalis even if associated with Candida albicans, Gardnerella vaginalis and other sensitive bacterial flora; Meclon vaginal solution can also be used after other topical or oral therapy, in order to reduce the risk of relapses.
Active ingredients
- 10ml bottle
10 ml contain: Active ingredient: Clotrimazole 200 mg.
- 130ml bottle
130 ml contain: Active ingredient: Metronidazole 1 g. Excipients: contains sodium methyl p-hydroxybenzoate and sodium propyl p-hydroxybenzoate.
Excipients
- 10ml bottle
Excipients: Ricinoleic alcohol; Ethanol; Purified water.
- 130ml bottle
Excipients: Sodium methyl p-hydroxybenzoate; Sodium propyl p-hydroxybenzoate; Purified water.
Contraindications
Hypersensitivity to the active substances or to any of the excipients.
Dosage of Alfasigma Meclon vaginal solution 5 bottles
Administer the ready vaginal solution once a day, preferably in the morning, or as prescribed by your doctor. During the attack phase, the use of the vaginal solution must be combined with appropriate topical and/or oral therapy. Irrigation should preferably be performed in a supine position. Slow emptying of the bottle will allow the active ingredients to remain in the vagina for longer and therefore provide a more effective antimicrobial and cleansing action. Instructions for use: After pouring the contents of the vial into the bottle, insert the vaginal cannula into the neck of the bottle. Insert the cannula into the vagina and administer the entire contents.
Pregnancy and breastfeeding
During pregnancy, the product should be used only in case of real need and under the direct supervision of a doctor.
Warnings
Avoid contact with eyes. Concomitant oral use of Metronidazole is subject to the contraindications, side effects and warnings described for the above-mentioned product. Avoid treatment with Meclon during menstruation. Cases of severe hepatotoxicity/acute liver failure, including fatal cases, with very rapid onset after initiation of treatment in patients with Cockayne syndrome have been reported with metronidazole-containing medicinal products for systemic use. Therefore, in this population metronidazole should be used after careful risk-benefit assessment and only in the absence of alternative treatments. Liver function tests should be performed just before the start of therapy, during and after the end of treatment, until liver function parameters have returned to normal or baseline values have been reached. If liver function test values increase significantly during treatment, the drug should be discontinued. Patients with Cockayne syndrome should be advised to immediately report to their physician any symptoms of potential liver injury and to discontinue treatment with metronidazole.
Interactions
None.
Side effects
Given the poor absorption of the active ingredients Metronidazole and Clotrimazole through local application, adverse reactions observed with topical formulations are limited to: Immune system disorders: Not known (frequency cannot be estimated from the available data): hypersensitivity reactions. Skin and subcutaneous tissue disorders: Very rare (frequency <1/10,000): local irritation phenomena such as itching, allergic contact dermatitis, skin rashes. Any occurrence of undesirable effects requires discontinuation of treatment.
Overdose
No symptoms of overdose have been described.
Format
Pack of 5 bottles of 130 ml + 5 bottles of 10 ml + 5 cannulas.
